Anifrolumab
Based on 7 publication(s) in Google Scholar
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.79%
- CAS No.: 1326232-46-5
- Masse moléculaire:144.92 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-P9917
TocilizumabIL-6R Neutralizing Antibody -
HY-P99191
EmapalumabIFN-γ Inhibitor -
HY-P990036
DazukibartMonoclonal Antibody -
HY-P9908
AdalimumabTNF-α Inhibitor -
HY-P9913
RituximabCD20 Inhibitor -
HY-P99001
Human IgG1 kappa, Isotype ControlIgG1κ Isotype Control -
HY-P9904
AtezolizumabAnti-PD-L1 Antibody -
HY-50856
RuxolitinibJAK1/2 Inhibitor -
HY-117287
DeucravacitinibTYK2 Inhibitor -
HY-P9945
MepolizumabIL-5 Inhibitor -
HY-15315
BaricitinibJAK1/2 Inhibitor -
HY-108841
RaleukinIL-1R Antagonist
Publications Citing Use of MedChemExpress (MCE) Anifrolumab
More
Customer Validation & Images
-
ELISA
-
RT-PCR
-
Flow Cytometry
-
RT-PCR
-
Flow Cytometry
Activité biologique
Description
Isotype
Human IgG1 (L234F/L235E/P331S) kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
IFNAR1
In Vitro
Anifrolumab (67.7 nM; 20 min) induces sustained reduction of surface IFNAR1 and abrogates STAT1 phosphorylation[2].
Anifrolumab (1 and 10 μg/mL; 6 or 7 d) suppresses differentiation of B cells into plasma cells[2].
Anifrolumab inhibits type I IFN-induced ISRE signaling, with IC50s ranging from 0.004 to 0.3 nM for the IFN-α subtypes, and 0.03 nM and 0.07 nM for IFN-β and IFN-ω, respectively[2].
Anifrolumab (67.7 nM) dose-dependently inhibits IFN-α production from pDCs in response to CpG-A or DNA-IC stimulation, inhibiting 87-95% of IFN-α production[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Peripheral blood mononuclear cells (PBMCs)
-
Concentration:67.7 nM
-
Incubation Time:20 min
-
Result:Abrogated IFN-α2-dependent and pDC supernatant-dependent STAT1 phosphorylation.
-
Cell Line:Plasmacytoid dendritic cell (pDC)
-
Concentration:1 and 10 μg/mL
-
Incubation Time:6 or 7 days
-
Result:Inhibited pDC-mediated plasma cell differentiation in a dose-dependent manner, with a mean 76% reduction in plasma cell number relative to control antibody.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized IFNAR1 Protein, Human (HEK293, His, HY-P70483) can bind Anifrolumab. The EC50 for this effect is 21.2 ng/mL. -
Flow cytometric analysis of 1.5X106 U937 cells with Anifrolumab (HY-P99168, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 1326232-46-5
-
Appearance Liquid
-
Masse moléculaire 144.92 kDa
-
Color Colorless to light yellow
-
SMILES
[Anifrolumab]
-
Synonyms
MDX-1333; MEDI-546
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Nat Immunol
A spatially coordinated keratinocyte-fibroblast circuit recruits MMP9+ myeloid cells to drive type I interferon-driven inflammation in photosensitive autoimmunity. [Abstract]2026 Jun;27(6):1184-1196. PMID: 42032302 -
-
Nat Commun
Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade. [Abstract]2024 Aug 26;15(1):7165. PMID: 39187481
Anifrolumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 26;15(1):7165. [Abstract]
Anifrolumab (10 µg/ml, 2 h) suppressed PDCD1 gene expression in A2058 human melanoma cells.
Anifrolumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 26;15(1):7165. [Abstract]
Anifrolumab (10 µg/ml, 2 h) suppressed IFN-α-dependent PD-1 expression in A2058 human melanoma cells.
-
-
Cell Prolif
Modelling myocardial ischemia/reperfusion injury with inflammatory response in human ventricular cardiac organoids. [Abstract]2025 Mar;58(3):e13762. PMID: 39377453
Anifrolumab purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2025 Mar;58(3):e13762. [Abstract]
Anifrolumab (1 or 10 µg/ml) reversed the H/R‑induced increase in the secretion of type I IFNs (including IFN‑α and IFN‑β) into the culture medium of ventricular cardiac organoids and co‑cultured THP‑1 cells.
Anifrolumab purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2025 Mar;58(3):e13762. [Abstract]
Anifrolumab (1 or 10 µg/ml) downregulated the expression of type I IFN-related genes in ventricular cardiac organoids and co‑cultured THP‑1 cells.
Anifrolumab purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2025 Mar;58(3):e13762. [Abstract]
Anifrolumab (1 or 10 µg/ml) decreased the H/R‑induced proportion of CD86+ cells and the mean fluorescence intensity of CD86 protein in ventricular cardiac organoids and co-cultured THP-1 cells.
-
-
bioRxiv
A Spatially Coordinated Keratinocyte-Fibroblast Circuit Recruits MMP9+ Myeloid Cells to Drive IFN-I-Driven Inflammation in Photosensitive Autoimmunity. [Abstract]2025 Aug 23:2025.08.19.670635. PMID: 40894544
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Furie R, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 Feb;69(2):376-386. [Content Brief]
[2]. Riggs JM, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018 Apr 5;5(1):e000261. [Content Brief]
Hot Topics
-
All
-
Topics
-
Most Recent
-
Oldest
-
Topics Regulation of Type I Interferon in the Prevention and Treatment of Viral and Inflammatory Diseases
Regulation of type I interferon in the prevention and treatment of viral and inflammatory diseases refers to the control of interferon-α and interferon-β production, signaling, and biological activity to balance antiviral defense with immune homeostasis.
2026-06-18
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anifrolumab Related Classifications
HY-P99168 Related Classifications
Powered by Bioz